Immunoglobulin D multiple myeloma: Response to therapy, survival, and prognostic factors in 75 patients

Annals of Oncology

Volumn 22, Issue 2, 2011, Pages 411-416

  Kim, M K ^a   Suh, C ^b   Lee, D H ^b   Min, C K ^c   Kim, S J ^d   Kim, K ^d   Moon, J H ^e   Yoon, S S ^f   Lee, G W ^g   Kang, H J ^h   Kim, S H ⁱ   Choi, C W ^j   Eom, H S ^k   Kwak, J Y ^l   Kim, H J ^m   Mun, Y C ⁿ   Bang, S M ^o   Lee, K ^p   Shin, H J ^q   Lee, J H ^r  

^a Yeungnam University Hospital   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e Kyungpook National University Hospital   (South Korea)

^f Seoul National University Hospital   (South Korea)

^g Gyeongsang National University School of Medicine   (South Korea)

^h Korea Cancer Center Hospital   (South Korea)

ⁱ Dong A University College of Medicine   (South Korea)

^j Korea University Ansan Hospital   (South Korea)

^k National Cancer Center of Korea   (South Korea)

^l Jeonbuk National University Medical School and Hospital   (South Korea)

^m Hallym University Medical Center   (South Korea)

ⁿ Ewha Womans University School of Medicine   (South Korea)

^o Seoul National University Bundang Hospital   (South Korea)

^p The Catholic University of Korea   (South Korea)

^q Pusan National University School of Medicine   (South Korea)

^r Gachon University College of Medicine   (South Korea)

more..

Author keywords

Immunoglobulin D; Multiple myeloma; Treatment outcome

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER REGISTRY; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HEPATOSPLENOMEGALY; HUMAN; HYPERCALCEMIA; IMMUNOGLOBULIN D MULTIPLE MYELOMA; KIDNEY DISEASE; KIDNEY FUNCTION; KOREA; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLASMACYTOMA; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTE COUNT;

EID: 79251592569     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq393     Document Type: Article

References (19)

1. Jancelewicz Z, Takatsuki K, Sugai S, Pruzanski W. IgD multiple myeloma. Review of 133 cases. Arch Intern Med 1975; 135: 87-93.
2. Shimamoto Y, Anami Y, Yamaguchi M. A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients. Eur J Haematol 1991; 47: 262-267.
3. Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol 1994; 12: 2398-2404.
4. Barlogie B, Shaughnessy J, Tricot G et al. Treatment of multiple myeloma. Blood 2004; 103: 20-32.
5. Wechalekar A, Amato D, Chen C et al. IgD multiple myeloma-a clinical profile and outcome with chemotherapy and autologous stem cell transplantation. Ann Hematol 2005; 84: 115-117.
6. Chong YP, Kim S, Ko OB et al. Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience. J Korean Med Sci 2008; 23: 819-824.
7. Hayashi T, Yamaguchi I, Saitoh H et al. Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis. Intern Med 2003; 42: 605-608.
8. Schmielau J, Teschendorf C, Konig M et al. Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma. Leuk Lymphoma 2005; 46: 567-569.
9. Greipp PR, San Miguel J, Durie BG et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
10. Munshi NC. Investigative tools for diagnosis and management. Hematology Am Soc Hematol Educ Program 2008: 298-305.
11. Fonseca R, Bergsagel PL, Drach J et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23: 2210-2221.
12. Kim SJ, Kim K, Kim BS et al. Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry. Acta Haematol 2009; 122: 200-210.
13. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
14. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
15. Kuliszkiewicz-Janus M, Zimny A, Sokolska V et al. Immunoglobulin D myeloma-problems with diagnosing and staging (own experience and literature review). Leuk Lymphoma 2005; 46: 1029-1037.
16. Maisnar V, Hàjek R, Scudla V et al. High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma. Bone Marrow Transplant 2008; 41: 51-54.
17. Tricot G, Barlogie B, Jagannath S et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86: 4250-4256.
18. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9.
19. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-1873.